The treatment of tardive dyskinesia with baclofen |
| |
Authors: | Glazer W. M. Moore D. C. Bowers M. B. Bunney B. S. Roffman M. |
| |
Affiliation: | (1) Department of Psychiatry, Yale University School of Medicine, 34 Park Street, 06519 New Haven, CT, USA;(2) UMDMJ-Rutgers Medical School and Department of Clinical Research, CIBA-GEIGY Corporation, USA |
| |
Abstract: | Thirty-one psychiatric outpatients with tardive dyskinesia (TD) on neuroleptic medication were followed in a double-blind, randomized trial comparing baclofen (30–90 mg per day) to placebo. A repeated measures analysis of variance revealed no statistical difference between the baclofen-treated group and the placebo group for the group and the placebo group for the total Abnormal Involuntary Movement Scale (AIMS) scores. There was a trend (P=0.09) for an initial improvement, then a worsening of frequency counts across four visits. The authors attempt to explain this finding on the basis of information obtained from animal research.UMDMJ-Rutgers Medical School and Department of Clinical Research, CIBA-GEIGY Corporation |
| |
Keywords: | Baclofen Tardive dyskinesia Dopamine |
本文献已被 SpringerLink 等数据库收录! |
|